Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A | P35348 | 3/20 | 0.50 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.48 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.42 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 3/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7638902 | 1.00 | ADRA1A (0.50) | ADRA1ACTDSP1ADRA1DADRA1BGAA | |
| SCHEMBL7082388 | 0.89 | CTDSP1 (0.58) | ADRA1ACTDSP1ADRA1DADRA1BGAA | |
| SCHEMBL6645152 | 0.89 | CTDSP1 (0.58) | ADRA1ACTDSP1ADRA1DADRA1BGAA | |
| SCHEMBL7082385 | 0.89 | CTDSP1 (0.58) | ADRA1ACTDSP1ADRA1DADRA1BGAA | |
| SCHEMBL6346169 | 0.82 | HTT (0.54) | CTDSP1GAAPKMKMT2AMEN1 | |
| SCHEMBL7669646 | 0.82 | ADRA1A (0.42) | ADRA1AADRA1DADRA1B | |
| SCHEMBL7686416 | 0.82 | ADRA1A (0.42) | ADRA1AADRA1DADRA1B | |
| SCHEMBL19732929 | 0.80 | USP2 (0.52) | GAAKDM4EPKM | |
| SCHEMBL2570938 | 0.80 | USP2 (0.52) | GAAKDM4EPKM | |
| SCHEMBL7660049 | 0.80 | USP2 (0.52) | GAAKDM4EPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6339090-B1 | FOR THERAPY OF BENIGN PROSTATIC HYPERPLASIA | MERCK & CO., INC. | 2002-01-15 | — | — | US | claimed |
| WO-2000006565-A1 | ALPHA 1a ADRENERGIC RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2000-02-10 | — | — | WO | claimed |
| US-20040242609-A1 | Selective melanin concentrating hormone-1 (MCH1) receptor antagonists and uses thereof | SYNAPTIC PHARMACEUTICAL CORPORATION | 2004-12-02 | — | — | US | disclosed |
| WO-2004064774-A2 | DNA ENCODING A HUMAN MELANIN CONCENTRATING HORMONE RECEPTOR (MCH1) AND USES THEREOF | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 2004-08-05 | — | — | WO | disclosed |
| US-6720324-B2 | THERAPY FOR EATING DISORDERS, SEXUAL DISORDERS, PSYCHOLOGICAL DISORDERS | SYNAPTIC PHARMACEUTICAL CORPORATION | 2004-04-13 | — | — | US | disclosed |
| US-20040038855-A1 | DNA encoding a human melanin concentrating hormone receptor (MCH1) and uses thereof | H. LUNDBECK A/S (DK) | 2004-02-26 | — | — | US | disclosed |
| US-20030082623-A1 | DNA encoding a human melanin concentrating hormone receptor (MCH1) and uses thereof | H. LUNDBECK A/S (DK) | 2003-05-01 | — | — | US | disclosed |
| US-20030077701-A1 | DNA encoding a human melanin concentrating hormone receptor (MCH1) and uses thereof | H. LUNDBECK A/S (DK) | 2003-04-24 | — | — | US | disclosed |
| US-20030069261-A1 | Selective melanin concentrating hormone-1 (MCH1) receptor antagonists and uses thereof | H. LUNDBECK A/S (DK) | 2003-04-10 | — | — | US | disclosed |
| US-6339090-B1 | FOR THERAPY OF BENIGN PROSTATIC HYPERPLASIA | MERCK & CO., INC. | 2002-01-15 | — | — | US | disclosed |
| WO-2000006565-A1 | ALPHA 1a ADRENERGIC RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2000-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030082623-A1 | DNA encoding a human melanin concentrating hormone receptor (MCH1) and uses thereof | MCHR1, MCHR2, MC1R | ADRA1A 224/4885CTDSP1 1296/4885ADRA1D 247/4885 |
| US-20040038855-A1 | DNA encoding a human melanin concentrating hormone receptor (MCH1) and uses thereof | MCHR1, MCHR2, MC1R | ADRA1A 88/4885CTDSP1 1405/4885ADRA1D 100/4885 |
| US-20040242609-A1 | Selective melanin concentrating hormone-1 (MCH1) receptor antagonists and uses thereof | MCHR1, MCHR2, MC4R | ADRA1A 161/4885CTDSP1 4793/4885ADRA1D 149/4885 |
| US-20030077701-A1 | DNA encoding a human melanin concentrating hormone receptor (MCH1) and uses thereof | MCHR1, MCHR2, MC1R | ADRA1A 224/4885CTDSP1 1296/4885ADRA1D 247/4885 |
| US-20030069261-A1 | Selective melanin concentrating hormone-1 (MCH1) receptor antagonists and uses thereof | MCHR1, MCHR2, MC4R | ADRA1A 161/4885CTDSP1 4793/4885ADRA1D 149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.